A Study of JNJ-89402638 for Metastatic Colorectal Cancer
Last Updated June 18, 2025
Want to learn how to participate in this trial?
89402638GIC1001
OVERVIEW
-
Sexes Eligible for Study
all -
Age
years -
Phase
phase 1 -
Sites
Sites -
Status
Recruiting
SUMMARY
The purpose of this study is to determine the putative recommended phase 2 dose(s) (RP2Ds) of JNJ-89402638 and to determine the safety of JNJ-89402638 at the RP2D(s) in participants with metastatic colorectal cancer.
CONDITIONS
- Unresectable Metastatic Colorectal Cancer
ELIGIBILITY
Inclusion Criteria:
* Have histologically or cytologically confirmed diagnosis of colorectal adenocarcinoma (CRC) progressing after 2 or more prior lines of standard therapy in the metastatic/unresectable setting
* Have evaluable or measurable disease per response evaluation crit
DETAILS
LOCATIONS
| Country (3) | City or Province (8) | Status |
| United States | Sarasota Florida Cancer Specialists |
RECRUITING
|
| United States | Grand Rapids Start Midwest |
RECRUITING
|
| United States | Aurora University of Colorado Denver Anschultz Medical Campus |
RECRUITING
|
| United States | Indianapolis Community Health Network |
RECRUITING
|
| South Korea | Seoul Severance Hospital Yonsei University Health System |
SUSPENDED
|
| South Korea | Seoul Asan Medical Center |
SUSPENDED
|
| Spain | Madrid Hosp Univ Hm Sanchinarro |
RECRUITING
|
| Spain | Barcelona Hosp Univ Vall D Hebron |
RECRUITING
|
27.33643, -82.53065
42.96336, -85.66809
39.72943, -104.83192
39.76838, -86.15804
37.566, 126.9784
37.566, 126.9784
40.4165, -3.70256
41.38879, 2.15899
Indicates 50+ sites in this region: click to zoom in.
Indicates 10+ sites in this region: click to zoom in.
Indicates < 10 sites in this region: click to zoom in.
Corresponds to individual site.